Production (Stage)
Allogene Therapeutics, Inc.
ALLO
$1.06
-$0.03-2.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -59.73M | -59.94M | -66.29M | -66.36M | -65.00M |
| Total Depreciation and Amortization | 3.10M | 3.23M | 3.21M | 3.64M | 3.56M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 12.00M | 14.74M | 27.85M | 15.88M | 11.20M |
| Change in Net Operating Assets | -8.29M | 5.27M | -8.88M | -16.75M | -5.65M |
| Cash from Operations | -52.93M | -36.70M | -44.12M | -63.59M | -55.90M |
| Capital Expenditure | -99.00K | -257.00K | -429.00K | 0.00 | -8.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.28M | 55.19M | -75.56M | 74.61M | 22.14M |
| Cash from Investing | 6.18M | 54.93M | -75.99M | 74.61M | 22.13M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.64M | 5.74M | 679.00K | 106.32M | 1.65M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.35M | 0.00 | 0.00 | 2.28M | -- |
| Cash from Financing | 13.99M | 5.74M | 679.00K | 108.60M | 1.65M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -32.76M | 23.98M | -119.43M | 119.63M | -32.12M |